Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.

2.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
3.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

4.

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD.

Psychopharmacology (Berl). 2006 Dec;189(2):259-66. Epub 2006 Oct 21.

PMID:
17058105
5.

Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.

Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, McQuade RD, Crandall DT, Carson WH, Marcus RN, L'italien G.

Schizophr Res. 2008 Dec;106(2-3):300-7. doi: 10.1016/j.schres.2008.09.002. Epub 2008 Oct 29.

6.

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Swainston Harrison T, Perry CM.

Drugs. 2004;64(15):1715-36. Review.

PMID:
15257633
7.

The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.

Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R.

J Clin Psychiatry. 2009 Mar;70(3):318-25. Epub 2008 Dec 16.

PMID:
19192469
8.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

9.

Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.

Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:260-6. doi: 10.1016/j.pnpbp.2012.10.010. Epub 2012 Oct 18.

PMID:
23085073
10.

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.

Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH.

Biol Psychiatry. 2009 Mar 15;65(6):510-7. doi: 10.1016/j.biopsych.2008.07.033. Epub 2008 Nov 4.

PMID:
18986646
11.

Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.

L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN.

J Clin Psychiatry. 2007 Oct;68(10):1510-6.

PMID:
17960964
12.

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM.

J Clin Psychopharmacol. 2009 Aug;29(4):362-7. doi: 10.1097/JCP.0b013e3181ac9b0b.

PMID:
19593176
13.

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.

Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J.

J Clin Psychopharmacol. 2008 Dec;28(6):601-7. doi: 10.1097/JCP.0b013e31818aaf6c.

PMID:
19011427
14.

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.

Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A.

J Clin Psychiatry. 2009 Apr;70(4):572-81. Epub 2009 Mar 24.

PMID:
19323965
15.

Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.

Chen CH, Huang MC, Lu ML.

J Clin Psychopharmacol. 2007 Oct;27(5):516-7. No abstract available.

PMID:
17873689
16.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
18.

Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.

Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD.

Eur Psychiatry. 2008 Dec;23(8):561-6. doi: 10.1016/j.eurpsy.2008.01.1421. Epub 2008 Apr 18.

PMID:
18374544
19.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
20.

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T.

Schizophr Res. 2003 Jun 1;61(2-3):123-36.

PMID:
12729864

Supplemental Content

Support Center